Accuray Incorporated (NASDAQ:ARAY) Q3 2021 Earnings Conference Call April 27, 2021 4:30 PM ET Company Participants Ken Mobeck – Vice President-Finance and Investor Relations Josh Levine – President and Chief Executive Officer Shig Hamamatsu – Senior Vice President and Chief Financial Officer Suzanne Winter – Senior Vice President-Research and Development and Chief Commercial Officer Conference Call Participants Josh Jennings – Cowen Brooks O'Neil – Lake Street Capital Markets Anthony Petrone – Jefferies Ope ...

市场需求与机会 - 2021年全球癌症新病例达到1800万，预计到2035年需要增加7700台放射治疗设备以满足需求[13] - 中国每年新增癌症病例430万，是美国的2.5倍，放射治疗的需求尚未得到充分满足[14] - 预计到2035年，接受放射治疗的患者数量将增加150%[13] - Accuray在中国的市场机会预计将以约10%的年增长率增长，以满足WHO的指导方针[15] 产品与技术创新 - Accuray的Radixact系统通过Synchrony®和ClearRT™技术实现市场差异化，推动创新[8] - Accuray的ClearRT™技术已获得FDA 510(k)认证，提升放射治疗的成像质量[26] - Accuray的CyberKnife® S7™平台在立体定向放射外科和立体定向放射治疗中提供行业领先的精确度[32] - 公司正在开发基于框架的神经技术，尚未承诺交付产品[34] 财务表现与估值 - Accuray的市场资本为387.9百万美元，负债为95.5百万美元，企业价值为179.7百万美元[41] - Accuray的销售额（TTM）为378.7百万美元，EV/Sales比率为1.25[41] - Accuray的EV/Sales比率相比于放射治疗同行组的平均值（7.73）存在83.87%的折扣[41] - Accuray的现金储备为387.9百万美元，显示出良好的流动性[41] 未来展望与战略 - Accuray计划在未来三年内每年推出新产品，以扩大市场份额[9] - 公司预计运营杠杆将推动长期盈利增长和持续的创新投资[37] - 公司专注于价值创造，执行是其首要任务[39] - 公司预计长期收入增长催化剂将为强劲回报奠定基础[39] - 公司正在扩大其安装基础，以提供稳定的年度服务收入[36] - 公司在老化伽马刀替换机会方面具备竞争优势，能够提供全颅脊神经外科能力[35] 竞争与市场环境 - 美国放射治疗设备的中位年龄超过8年，82%的购买为替换设备[20] - Accuray在中国的联合企业已获得58个类型A许可证中的50个，累计获胜率达到82%[8]

市场趋势与需求 - 全球癌症新病例在2018年达到1800万，预计到2035年需要21800台直线加速器以满足放射治疗的需求[26] - 预计到2035年，接受放射治疗的患者数量将增加150%[26] - 预计到2035年，全球放射治疗市场将迎来显著增长，特别是在中国市场[33] 业绩与收入 - Accuray在过去六个财政年度中每年产生超过2亿美元的服务收入[17] - Accuray在第一轮中获得了86%的Type A许可证，具体为581个中获得50个[40] 产品与技术创新 - Accuray的产品组合包括CyberKnife®和TomoTherapy®，提供超精确的放射治疗解决方案[14] - Accuray的全球专利组合包括约472项美国和外国专利，以及约129项专利申请[20] - Radixact®系统的Synchrony®技术允许在治疗过程中实时监测目标位置，提高治疗的精确度和效率[71] - Accuray的ClearRT™成像技术正在开发中，旨在提高放射治疗的成像质量和效率[84] - CyberKnife S7系统具备行业领先的精确度，能够快速规划和交付治疗[112] 合作与市场扩张 - Accuray在中国获得58个类型A许可证中的50个，并建立了合资企业[21] - Accuray的中国合资企业于2019年成立，49%由Accuray拥有，51%由中国同位素与辐射公司拥有[36] - 预计在2023财年将员工扩展至约200人[39] 未来展望与策略 - Accuray的产品创新和市场渗透策略将推动长期增长[21] - 预计Accuray的创新技术将提高每年治疗的患者数量，缩短总治疗时间，降低治疗相关成本[59] - 公司致力于通过新产品创新提升个性化和缩短治疗时间[131] 负面信息与挑战 - 30%的所有放射治疗病例将由传统医疗保险支付，适用16种诊断，涵盖约90%的适应症[49] - RO-APM预计将节省约2.3亿美元，通过将支付转向基于诊断的支付模式[49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

Accuray Incorporated (NASDAQ:ARAY) Q1 2021 Results Conference Call October 29, 2020 4:30 PM ET Company Participants Joe Diaz - IR, Lytham Partners Josh Levine - President and CEO Shig Hamamatsu - SVP and CFO Suzanne Winter - Chief Commercial Officer and Head, R&D Conference Call Participants Brooks O’Neil - Lake Street Capital Markets Marie Thibault - BTIG Anthony Petrone - Jeffries Operator Good Day, and welcome to the Accuray First Quarter Fiscal 2020 Financial Results Conference Call. All participants wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33301 ACCURAY INCORPORATED (Exact name of registrant as specified in its charter) DELAWARE 20-8370041 (State or Other Jurisdiction of Inc ...

Accuray Incorporated (NASDAQ:ARAY) Q4 2020 Results Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Joseph Diaz - Managing Partner, Lytham Partners Joshua Levine - President & CEO Shigeyuki Hamamatsu - SVP & CFO Suzanne Winter - Chief Commercial Officer & Head of R&D Conference Call Participants Josh Jennings - Cowen Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon. Welcome to the Accuray Report Fourth Quarter and Fiscal Year 2020 Financial Results Conference Call. ...